FibroGen, Inc. Files 8-K Report

TL;DR

FibroGen filed an 8-K for 'Other Events' - need more info.

AI Summary

On November 6, 2025, FibroGen, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or involved parties were provided in the excerpt.

Why It Matters

This 8-K filing signals that FibroGen, Inc. has reported a material event. Investors and stakeholders should monitor future filings for details on the nature and impact of this event.

Risk Assessment

Risk Level: medium — The filing of an 8-K for 'Other Events' without immediate detail introduces uncertainty, requiring further information to assess potential risks.

Key Players & Entities

• FibroGen, Inc. (company) — Registrant
• November 06, 2025 (date) — Date of earliest event reported
• 350 Bay Street Suite 100 #6009 (location) — Principal Executive Offices Address
• San Francisco, California (location) — Principal Executive Offices City and State
• 94133 (location) — Principal Executive Offices Zip Code
• 415 978-1200 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
• $6.4 million — broGen, Inc. (the "Company") received a $6.4 million payment from AstraZeneca Treasury Limit
• $0.4 million — (the "Share Purchase Agreement"), plus $0.4 million that was an additional payment followin
• $220 million — a total consideration of approximately $220 million comprised of $85 million in enterprise
• $85 million — approximately $220 million comprised of $85 million in enterprise value and approximately $
• $135 million — n in enterprise value and approximately $135 million in net cash held in China. The total co
• $210 million — China. The total consideration included $210 million paid at closing, and $10.0 million paya
• $10.0 million — luded $210 million paid at closing, and $10.0 million payable by AstraZeneca after closing an
• $6.0 million — llowing holdbacks and conditions: (i) a $6.0 million holdback to offset final net cash adjus
• $4.0 million — ustomary adjustment process, and (ii) a $4.0 million holdback to satisfy any indemnity claim

Filing Documents

• fgen-20251106.htm (8-K) — 43KB
• 0001193125-25-269529.txt ( ) — 145KB
• fgen-20251106.xsd (EX-101.SCH) — 24KB
• fgen-20251106_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On November 6, 2025, FibroGen, Inc. (the "Company") received a $6.4 million payment from AstraZeneca Treasury Limited ("AstraZeneca"). This amount is in full satisfaction of the first holdback set forth in the share purchase agreement entered into between the Company and AstraZeneca on February 20, 2025 (the "Share Purchase Agreement"), plus $0.4 million that was an additional payment following the final net cash adjustments after closing. On August 29, 2025, the Company closed the sale of its China operations through FibroGen International (Hong Kong) Ltd. to AstraZeneca pursuant to the Share Purchase Agreement for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China. The total consideration included $210 million paid at closing, and $10.0 million payable by AstraZeneca after closing and subject to the following holdbacks and conditions: (i) a $6.0 million holdback to offset final net cash adjustments, which was released today, following a customary adjustment process, and (ii) a $4.0 million holdback to satisfy any indemnity claims, which will be released, net of any claims paid or unresolved, nine months after the closing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: November 6, 2025 By: /s/ John Alden John Alden General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR